Abstract
For targeted radionuclide therapy to succeed as a single modality treatment, schemes must be devised which will enable the deposition in malignant cells of sterilising doses of radiation. Until such methods have been perfected, it is necessary to combine targeted radiotherapy in a rational manner with conventional anti-cancer treatments. Several means of delivery of therapeutic radionuclides are being evaluated but none of these yet appears to be as powerful as the simplest and most effective example, viz sodium ( 131 I)iodide treatment of disseminated thyroid carcinoma. The radiopharmaceutical ( 131 I)meta-iodobenzylguanidine ( 131 I MIBG) is an effective single agent for the treatment of neuroblastoma. However, uptake of the drug in malignant sites is heterogeneous, suggesting that this therapy alone is unlikely to cure disease. A growing body of experimental evidence indicates exciting possibilities for the integration of gene transfer with radionuclide targeting. This review covers aspects of the combination of gene manipulation and targeted radiotherapy, emphasising the potential of gene transfer to facilitate tumour targeting with low molecular weight radiopharmaceuticals.
Keywords: Gene Transfer, Targeted Radiotherapy, Neuroblastoma, Cytotoxic radionuclides, Antigen Gene Expression, Antibody Targeting, Carcinoembryonic antigen, Radiolabelled, Tumours, Anti mouse immunoglobulin responses, Receptor gene expression, Peptide Targeting, Sodium iodide symporter gene transfection, Tumour cells, Noradrenaline transporter, UVW NIS, UVW GFP, Untransfected UVW spheroids, Mosaic spheroid, NAT transfectants, GFP transfected, MIBG interactions, Sequencing, Radiological bystander effect
Current Pharmaceutical Design
Title: Applications of Gene Transfer to Targeted Radiotherapy
Volume: 6 Issue: 14
Author(s): R. J. Mairs, S. H. Cunningham, M. Boyd and S. Carlin
Affiliation:
Keywords: Gene Transfer, Targeted Radiotherapy, Neuroblastoma, Cytotoxic radionuclides, Antigen Gene Expression, Antibody Targeting, Carcinoembryonic antigen, Radiolabelled, Tumours, Anti mouse immunoglobulin responses, Receptor gene expression, Peptide Targeting, Sodium iodide symporter gene transfection, Tumour cells, Noradrenaline transporter, UVW NIS, UVW GFP, Untransfected UVW spheroids, Mosaic spheroid, NAT transfectants, GFP transfected, MIBG interactions, Sequencing, Radiological bystander effect
Abstract: For targeted radionuclide therapy to succeed as a single modality treatment, schemes must be devised which will enable the deposition in malignant cells of sterilising doses of radiation. Until such methods have been perfected, it is necessary to combine targeted radiotherapy in a rational manner with conventional anti-cancer treatments. Several means of delivery of therapeutic radionuclides are being evaluated but none of these yet appears to be as powerful as the simplest and most effective example, viz sodium ( 131 I)iodide treatment of disseminated thyroid carcinoma. The radiopharmaceutical ( 131 I)meta-iodobenzylguanidine ( 131 I MIBG) is an effective single agent for the treatment of neuroblastoma. However, uptake of the drug in malignant sites is heterogeneous, suggesting that this therapy alone is unlikely to cure disease. A growing body of experimental evidence indicates exciting possibilities for the integration of gene transfer with radionuclide targeting. This review covers aspects of the combination of gene manipulation and targeted radiotherapy, emphasising the potential of gene transfer to facilitate tumour targeting with low molecular weight radiopharmaceuticals.
Export Options
About this article
Cite this article as:
Mairs J. R., Cunningham H. S., Boyd M. and Carlin S., Applications of Gene Transfer to Targeted Radiotherapy, Current Pharmaceutical Design 2000; 6 (14) . https://dx.doi.org/10.2174/1381612003399194
DOI https://dx.doi.org/10.2174/1381612003399194 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer’s disease
Current Alzheimer Research From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Editorial (Hot Topic: Survival Signaling Through Focal Adhesion Kinase in Tumors)
Anti-Cancer Agents in Medicinal Chemistry (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Current Topics in Medicinal Chemistry Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry MicroRNA in Cervical Carcinogenesis: Window of Therapeutic Potential
Current Women`s Health Reviews Fluorescent GPCR Ligands as New Tools in Pharmacology-Update, Years 2008- Early 2014
Current Medicinal Chemistry Production and Application of Copper Radiopharmaceuticals
Current Radiopharmaceuticals Carotenoids and Modulation of Cancer: Molecular Targets
Current Pharmacogenomics Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets EZN-2208 (PEG-SN38), A 40 kDa Polyethylene Glycol (PEG) Conjugate, As an Anticancer Agent: Review of Preclinical and Clinical Data
Current Bioactive Compounds Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Current Pharmaceutical Design Protective Effects of Caffeic Acid and the Alzheimer's Brain: An Update
Mini-Reviews in Medicinal Chemistry Safety of Nanoparticles in Medicine
Current Drug Targets Targeted Hydrolysis of Beta-Amyloid with Engineered Antibody Fragments
Current Alzheimer Research Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins
Anti-Cancer Agents in Medicinal Chemistry